Valeant Pharmaceuticals International has entered into an agreement with Nestle to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Read the full story

Galderma is a top pharmaceutical company based in Lausanne, Switzerland. Read the full story

Bioventus has entered into pharma deal with Galderma to acquire the international assets for DUROLANE. Read the full story

Galderma is one of the top global pharmaceutical companies with a dermatology focus area. Read the full story

Galderma is one of the world’s largest dermatology and top 50 pharma companies. Read the full story

Galderma, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years Read the full story

Valeant Pharmaceuticals International has reached agreement on terms of a revised pharma alliances aesthetics arrangement with North American Galderma. Read the full story

This report provides all the information you require to better understand Galderma and its partnering interests and activities over the past seven years Read the full story